Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) ...

TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, has been recognized by CIOReview as a Top ...

Rikers Island correction captains and officers revived a man who had overdosed on drugs, and a detainee with a long record of ...

After responding to call in Mea Shearim, paramedics returned to vehicle to find graffiti; Magen David Adom head decries ...

Medicaid serves lower-income adults, children, pregnant women, and people with disabilities, as well as dually-enrolled ...

“The KickStart Grant Awards help de-risk these technologies by establishing a collaboration agreement between the startup ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

sensitivity and safety (3S). These optimal 3S TCRs can subsequently be merged with a Cluster of Differentiation 3 (CD3) T cell engaging antibody. The TCR-TCEs specifically redirect the patient’s own T ...